J&J Expects Strong Annual Earnings Boosted by Cancer Treatment Success

On Tuesday, Johnson & Johnson surpassed earnings expectations for the first quarter and raised its profit forecast for 2023, banking on its newer cancer treatments and multiple myeloma drug Darzalex to offset declining demand for older medicines. Shares of Johnson & Johnson increased by over 2% during pre-market trading Key to achieving its $60 billion […]